Urinary tract cancer market was valued at $1.704 billion in 2020, and is estimated to reach $8.786 billion by 2030, growing at a CAGR of 18.6% from 2021 to 2030. Cancer is defined as an adverse disease that is caused due to abnormal cell growth, and possess the potential to spread to other body parts. Urinary tract cancer is a type of cancer found in the bladder, ureter, and urethra. The most common urinary tract cancer is bladder cancer. The aging population, smokers and workers in the chemical industry are more vulnerable to urinary tract infection.
๐๐ข๐ฌ๐ญ ๐จ๐ ๐๐๐ฒ ๐๐ฅ๐๐ฒ๐๐ซ๐ฌ :
Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lily and Company, Endo International plc., Exelixis, Inc., GlaxoSmithKline Plc. (GSK), Merck KGAA, Novartis AG, Pfizer Inc., Johnson & Johnson
๐๐จ๐ฐ๐ง๐ฅ๐จ๐๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐๐ฉ๐จ๐ซ๐ญ https://www.alliedmarketresearch.com/request-sample/612
๐๐ผ๐๐ถ๐ฑ-๐ญ๐ต ๐ฆ๐ฐ๐ฒ๐ป๐ฎ๐ฟ๐ถ๐ผ:
The COVID-19 outbreak is anticipated to have a negative impact on growth of the global urinary tract cancer market. The COVID-19 pandemic has stressed the healthcare systems in the world. Most hospital and cancer centers have reduced their outpatient capacity and conducting a triage to only select the patients that are in most need of a cystoscopy. This leads to cancellation of many non-essential surgical procedures across the world. A huge number of clinics, hospitals across the globe, were restructured to increase the hospital capacity for the patient diagnosed with COVID-19. According to Future Science OA, in September 2020, it was observed that the admission of a patient for urology, oncology or radiotherapy departments are avoided. Subsequently, this leads to decrease in demand for available therapy of urinary tract cancer and decrease the growth of the market.
๐
๐จ๐ซ ๐๐ฎ๐ซ๐๐ก๐๐ฌ๐ ๐๐ง๐ช๐ฎ๐ข๐ซ๐ฒ https://www.alliedmarketresearch.com/purchase-enquiry/612
Moreover, initiatives taken by governments for development of the healthcare infrastructure and rise in awareness about and treatment of cancer are the key factors that boost the growth of the market. Furthermore, an increase in the cost of healthcare and surge in the number of funding for various research centers propel the growth of the market. In addition, surge in number of workers in chemical industry fuel the market growth. These workers are more prone to urinary tract cancer, due to prolonged exposure to various chemical.
The urinary tract cancer market is segmented on the basis of cancer type, treatment type, distribution channel, and region. On the basis of cancer type, the market is divided into bladder cancer, urethral cancer and ureteric and renal pelvic cancer. The bladder cancer segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in healthcare expenditure, advancement in available therapies, and increase in prevalence of bladder cancer.
On the basis of treatment type, the market is classified into chemotherapy, and immunotherapy. The immunotherapy segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in incidence of cancer, a rise in the number of approvals, stringent government regulation and increase in number of smokers. On the basis of distribution channel, the market is classified into retail pharmacy, and online pharmacy. The retail pharmacy segment dominated the market in 2020, and is expected to continue this trend during the forecast period, owing to increase in number of hospital & oncology centers, rise in prevalence of cancer and rise in the number of drug approval for treatment of cancer.
๐๐๐ ๐
๐๐๐๐๐๐๐ ๐๐
๐๐๐ ๐๐๐๐๐
- By cancer type, the bladder cancer segment was the highest contributor to the market in 2020.
- By treatment type, the immunotherapy segment was the highest contributor to the market in 2020.
- By distribution channel, the retail pharmacy segment dominated the market in 2020 and is expected to continue this trend during the forecast period.
- By region, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.
๐๐ญ๐ก๐๐ซ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ:
About Us
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of โMarket Research Reportsโ and โBusiness Intelligence Solutions.โ AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact:
David Correa
5933 NE Win Sivers Drive
205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com